Dr. Wei Wang, MD, PHD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Virginia School of Medicine (1999)
- Years since graduation
- 27
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 136
Licensed in Washington since 2001, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1999Medical school: University of Virginia School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
CA license A95030 (first issued 2006; current) · WA license MD00039979 (first issued 2001; expired)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- California PAcific Medical Center- Van Ness Campus San Francisco, CA
- Legacy Meridian PArk Medical Center Tualatin, OR
- Providence Willamette Falls Medical Center Oregon City, OR
Medical groups
- San Francisco Oncology Associates Medical Group Inc (3 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 136
- Services billed
- 47,372
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, denosumab, 1 mg | 4,860 | 18 |
| Established patient office or other outpatient visit, 30-39 minutes | 216 | 90 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 213 | 40 |
| Insertion of needle into vein for collection of blood sample | 188 | 44 |
| Administration of chemotherapy into vein, 1 hour or less | 152 | 22 |
| Established patient office or other outpatient visit, 20-29 minutes | 150 | 101 |
| Infusion, normal saline solution, 250 cc | 101 | 13 |
| Injection, zoledronic acid, 1 mg | 73 | 15 |
| Injection of drug or substance under skin or into muscle | 71 | 22 |
| Established patient office or other outpatient visit, 40-54 minutes | 51 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in San Francisco, CA | 306 |
| Tagrisso (osimertinib mesylate) | 97 |
| Tamoxifen Citrate Other prescribers in San Francisco, CA | 73 |
| Trazimera (trastuzumab-qyyp) | 61 |
| Omeprazole Other prescribers in San Francisco, CA | 26 |
| Letrozole Other prescribers in San Francisco, CA | 22 |
| Pantoprazole Sodium Other prescribers in San Francisco, CA | 15 |
| Exemestane | 14 |
| Jakafi (ruxolitinib phosphate) | 13 |
| Calquence (acalabrutinib maleate) | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 23 companies reported 70 payments worth $2,029 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $360 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $210 |
| Merck Sharp & Dohme LLC | $183 |
| Pfizer Inc. | $180 |
| Array Biopharma Inc | $179 |
| Daiichi Sankyo Inc. | $139 |
| Eisai Inc. | $80.00 |
| AbbVie Inc. | $73.20 |
| Food and Beverage | $2,012 |
|---|---|
| Education | $17.22 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Dec 4, 2025 | Education IMFINZI · Oncology · in-kind Company’s descriptionJournal Article | $17.22 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $2,500 in research payments for these studies, mostly to the institutions running them.
- Study name not reported
Organon Llc
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.